- Home
- Publications
- Publication Search
- Publication Details
Title
RNA Silencing in the Management of Dyslipidemias
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume 23, Issue 11, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-01
DOI
10.1007/s11883-021-00968-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drucebo effect – the challenge we should all definitely face!
- (2021) Maciej Banach et al. Archives of Medical Science
- Cellular senescence, telomeres, and cardiovascular risk in familial hypercholesterolaemia
- (2021) Maciej Banach et al. European Journal of Preventive Cardiology
- Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
- (2021) R. Scott Wright et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies
- (2021) Maciej Banach et al. Current Atherosclerosis Reports
- Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
- (2021) Maciej Banach et al. PHARMACOLOGICAL RESEARCH
- An oral antisense oligonucleotide for PCSK9 inhibition
- (2021) Peter Gennemark et al. Science Translational Medicine
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
- (2020) Jan Borén et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- What's new in lipid‐lowering pharmacology? Integrating basic and clinical research to improve patient outcomes
- (2020) Peter E. Penson BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
- (2020) Ulf Landmesser et al. CARDIOVASCULAR RESEARCH
- Insights from ORION studies: focus on inclisiran safety
- (2020) Alberico L Catapano et al. CARDIOVASCULAR RESEARCH
- Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia
- (2020) G. Kees Hovingh et al. CIRCULATION
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
- (2020) Julius L. Katzmann et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Advances in oligonucleotide drug delivery
- (2020) Thomas C. Roberts et al. NATURE REVIEWS DRUG DISCOVERY
- Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
- (2020) Maciej Banach et al. PHARMACOLOGICAL RESEARCH
- LDL-C: lower is better for longer—even at low risk
- (2020) Peter E. Penson et al. BMC Medicine
- Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go
- (2020) Maciej Banach et al. JAMA Network Open
- Clinical implications and outcomes of the ORION Phase III trials
- (2020) Julia Brandts et al. Future Cardiology
- Genetic testing in familial hypercholesterolaemia: What does it add?
- (2019) Maciej Banach et al. European Journal of Preventive Cardiology
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel
- (2019) P Penson et al. EUROPEAN HEART JOURNAL
- Inclisiran—New hope in the management of lipid disorders?
- (2019) Krzysztof Dyrbuś et al. Journal of Clinical Lipidology
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
- (2019) R. Scott Wright et al. MAYO CLINIC PROCEEDINGS
- Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility
- (2018) Jayesh A. Kulkarni et al. Nucleic Acid Therapeutics
- Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study
- (2018) Peter Penson et al. CARDIOVASCULAR RESEARCH
- Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
- (2018) Peter E Penson et al. EUROPEAN HEART JOURNAL
- What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?
- (2018) Maciej Banach et al. CARDIOVASCULAR RESEARCH
- Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
- (2018) Peter E. Penson et al. Journal of Cachexia Sarcopenia and Muscle
- Entering the Modern Era of Gene Therapy
- (2018) Xavier M. Anguela et al. Annual Review of Medicine
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Evaluating bempedoic acid for the treatment of hyperlipidaemia
- (2017) Peter Penson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
- (2017) Mark J. Graham et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interpretation of the evidence for the efficacy and safety of statin therapy
- (2016) Rory Collins et al. LANCET
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
- (2014) Jayaprakash K. Nair et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Delivery materials for siRNA therapeutics
- (2013) Rosemary Kanasty et al. NATURE MATERIALS
- Knocking down barriers: advances in siRNA delivery
- (2009) Kathryn A. Whitehead et al. NATURE REVIEWS DRUG DISCOVERY
- Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor
- (2008) Oleg Khorev et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
- (2008) M. Frank-Kamenetsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now